Literature DB >> 35237927

Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives.

Masahiro Natsuaki1, Shinjo Sonoda2, Goro Yoshioka2, Hiroshi Hongo2, Tetsuya Kaneko2, Kuninobu Kashiyama2, Kensuke Yokoi2, Yutaka Hikichi3, Koichi Node2.   

Abstract

Antiplatelet therapy after percutaneous coronary intervention (PCI) has been changing in parallel with the development of drug-eluting stents (DES) and antiplatelet agents. The recommendation of dual antiplatelet therapy duration is getting shorter due to the decreased risk of stent thrombosis in new-generation DES, the use of a P2Y12 inhibitor as a monotherapy, and the increasing prevalence of high bleeding risk patients. Antithrombotic therapy after PCI has also changed due to the introduction of direct oral anticoagulants. Aspirin-free P2Y12 inhibitor monotherapy is now being evaluated in several prospective studies as a novel strategy of antiplatelet therapy after PCI. This review shows a current status and provides future perspectives for the antiplatelet therapy after PCI.
© 2022. The Author(s) under exclusive licence to Japanese Association of Cardiovascular Intervention and Therapeutics.

Entities:  

Keywords:  Antiplatelet therapy; Antithrombotic therapy; Percutaneous coronary intervention

Mesh：

Substances：

Year:  2022        PMID： 35237927     DOI： 10.1007/s12928-022-00847-1

Source DB:  PubMed          Journal:  Cardiovasc Interv Ther        ISSN： 1868-4297


  54 in total

1.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Authors:  Laura Mauri; Dean J Kereiakes; Robert W Yeh; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Sharon-Lise T Normand; Eugene Braunwald; Stephen D Wiviott; David J Cohen; David R Holmes; Mitchell W Krucoff; James Hermiller; Harold L Dauerman; Daniel I Simon; David E Kandzari; Kirk N Garratt; David P Lee; Thomas K Pow; Peter Ver Lee; Michael J Rinaldi; Joseph M Massaro
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry.

Authors:  Takeshi Kimura; Takeshi Morimoto; Yoshihisa Nakagawa; Kazuya Kawai; Shunichi Miyazaki; Toshiya Muramatsu; Nobuo Shiode; Masanobu Namura; Takahito Sone; Shigeru Oshima; Hideo Nishikawa; Yoshikazu Hiasa; Yasuhiko Hayashi; Masakiyo Nobuyoshi; Kazuaki Mitudo
Journal:  Circulation       Date:  2011-12-27       Impact factor: 29.690

Review 3.  Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.

Authors:  Tullio Palmerini; Giuseppe Biondi-Zoccai; Diego Della Riva; Christoph Stettler; Diego Sangiorgi; Fabrizio D'Ascenzo; Takeshi Kimura; Carlo Briguori; Manel Sabatè; Hyo-Soo Kim; Antoinette De Waha; Elvin Kedhi; Pieter C Smits; Christoph Kaiser; Gennaro Sardella; Antonino Marullo; Ajay J Kirtane; Martin B Leon; Gregg W Stone
Journal:  Lancet       Date:  2012-03-23       Impact factor: 79.321

4.  FDA panel, 7 and 8 December 2006 - The impact on our practice and research.

Authors:  Patrick W Serruys
Journal:  EuroIntervention       Date:  2007-02       Impact factor: 6.534

5.  Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial.

Authors:  Marco Valgimigli; Gianluca Campo; Monia Monti; Pascal Vranckx; Gianfranco Percoco; Carlo Tumscitz; Fausto Castriota; Federico Colombo; Matteo Tebaldi; Giuseppe Fucà; Moh'd Kubbajeh; Elisa Cangiano; Monica Minarelli; Antonella Scalone; Caterina Cavazza; Alice Frangione; Marco Borghesi; Jlenia Marchesini; Giovanni Parrinello; Roberto Ferrari
Journal:  Circulation       Date:  2012-03-21       Impact factor: 29.690

Review 6.  Drug-eluting stent thrombosis: current and future perspectives.

Authors:  Shoichi Kuramitsu; Shinjo Sonoda; Kenji Ando; Hiromasa Otake; Masahiro Natsuaki; Reo Anai; Yasuhiro Honda; Kazushige Kadota; Yoshio Kobayashi; Takeshi Kimura
Journal:  Cardiovasc Interv Ther       Date:  2021-01-13

7.  6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.

Authors:  Martine Gilard; Paul Barragan; Arif A L Noryani; Hussam A Noor; Talib Majwal; Thomas Hovasse; Philippe Castellant; Michel Schneeberger; Luc Maillard; Erwan Bressolette; Jaroslaw Wojcik; Nicolas Delarche; Didier Blanchard; Bernard Jouve; Olivier Ormezzano; Franck Paganelli; Gilles Levy; Joël Sainsous; Didier Carrie; Alain Furber; Jacques Berland; Oliver Darremont; Hervé Le Breton; Anne Lyuycx-Bore; Antoine Gommeaux; Claude Cassat; Alain Kermarrec; Pierre Cazaux; Philippe Druelles; Raphael Dauphin; Jean Armengaud; Patrick Dupouy; Didier Champagnac; Patrick Ohlmann; Knut Endresen; Hakim Benamer; Robert Gabor Kiss; Imre Ungi; Jacques Boschat; Marie-Claude Morice
Journal:  J Am Coll Cardiol       Date:  2014-11-16       Impact factor: 24.094

8.  Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial.

Authors:  Cheol Whan Lee; Jung-Min Ahn; Duk-Woo Park; Soo-Jin Kang; Seung-Whan Lee; Young-Hak Kim; Seong-Wook Park; Seungbong Han; Sang-Gon Lee; In-Whan Seong; Seung-Woon Rha; Myung-Ho Jeong; Do-Sun Lim; Jung-Han Yoon; Seung-Ho Hur; Yun-Seok Choi; Joo-Young Yang; Nae-Hee Lee; Hyun-Sook Kim; Bong-Ki Lee; Kee-Sik Kim; Seung-Uk Lee; Jei-Keon Chae; Sang-Sig Cheong; Il-Woo Suh; Hun-Sik Park; Deuk-Young Nah; Doo-Soo Jeon; Ki-Bae Seung; Keun Lee; Jae-Sik Jang; Seung-Jung Park
Journal:  Circulation       Date:  2013-10-04       Impact factor: 29.690

9.  Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial.

Authors:  Jean-Philippe Collet; Johanne Silvain; Olivier Barthélémy; Grégoire Rangé; Guillaume Cayla; Eric Van Belle; Thomas Cuisset; Simon Elhadad; François Schiele; Nicolas Lhoest; Patrick Ohlmann; Didier Carrié; Hélène Rousseau; Pierre Aubry; Jacques Monségu; Pierre Sabouret; Stephen A O'Connor; Jérémie Abtan; Mathieu Kerneis; Christophe Saint-Etienne; Farzin Beygui; Eric Vicaut; Gilles Montalescot
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321

10.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

Authors:  Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245
View more
  2 in total

Review 1.  Antithrombotic therapy after transcatheter aortic valve replacement.

Authors:  Yusuke Kobari; Taku Inohara; Kentaro Hayashida
Journal:  Cardiovasc Interv Ther       Date:  2022-09-17

2.  Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention.

Authors:  Hideki Kitahara; Kazuya Tateishi; Yuki Shiko; Yusuke Inaba; Yoshio Kobayashi; Takahiro Inoue
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.